Bank of The Ozarks lowered its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 23.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,628 shares of the company’s stock after selling 4,531 shares during the period. Bank of The Ozarks’ holdings in Teva Pharmaceutical Industries Limited were worth $486,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Schwab Charles Investment Management Inc. increased its position in shares of Teva Pharmaceutical Industries Limited by 7.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 241,571 shares of the company’s stock worth $8,025,000 after buying an additional 17,116 shares during the last quarter. Wetherby Asset Management Inc. increased its position in shares of Teva Pharmaceutical Industries Limited by 7.5% in the second quarter. Wetherby Asset Management Inc. now owns 9,374 shares of the company’s stock worth $311,000 after buying an additional 653 shares during the last quarter. Trent Capital Management Inc. NC bought a new position in shares of Teva Pharmaceutical Industries Limited during the second quarter worth about $4,724,000. HL Financial Services LLC increased its position in shares of Teva Pharmaceutical Industries Limited by 35.1% in the second quarter. HL Financial Services LLC now owns 21,239 shares of the company’s stock worth $706,000 after buying an additional 5,516 shares during the last quarter. Finally, Pictet Asset Management Ltd. increased its position in shares of Teva Pharmaceutical Industries Limited by 0.4% in the second quarter. Pictet Asset Management Ltd. now owns 3,026,485 shares of the company’s stock worth $84,318,000 after buying an additional 12,397 shares during the last quarter. 56.27% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 17.50 on Thursday. The firm’s 50-day moving average is $30.48 and its 200 day moving average is $31.78. Teva Pharmaceutical Industries Limited has a 1-year low of $17.47 and a 1-year high of $55.39. The company has a market cap of $17.78 billion, a PE ratio of 224.36 and a beta of 0.46.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. The company had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period last year, the company posted $1.25 earnings per share. Analysts predict that Teva Pharmaceutical Industries Limited will post $4.39 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th will be issued a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a dividend yield of 1.94%. The ex-dividend date is Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is presently -18.95%.

ILLEGAL ACTIVITY WARNING: “Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Bank of The Ozarks” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/teva-pharmaceutical-industries-limited-nyseteva-shares-sold-by-bank-of-the-ozarks/1470225.html.

A number of research analysts have issued reports on the stock. Zacks Investment Research downgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “strong sell” rating in a research report on Wednesday. Deutsche Bank AG reissued a “buy” rating and set a $28.00 price objective (down from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. Jefferies Group LLC reissued a “hold” rating and set a $26.00 price objective (down from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price objective (down from $31.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. Finally, Credit Suisse Group reissued an “outperform” rating and set a $39.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. Three equities research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited currently has an average rating of “Hold” and an average price target of $37.69.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.